Biopharma Co. Now at a Bargain Price, Analyst Says
Source: Dr. Andrew Uddin   (11/29/22)
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report. More >

Major Contract and Faster Commercialization for Chemicals Co.
Source: Penny Queen  (11/29/22)
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile. More >

Biopharma Co. Trades to New 52-Week High
Source: Streetwise Reports  (11/28/22)
Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints
in the Phase 3 ACCORD Alzheimer's disease agitation trial. More >

Pharma Co. Gains Approval for SARS-CoV-2 Drug
Source: Streetwise Reports  (11/23/22)
Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection. More >

Life Sciences Co. Exceeds Expectations in Q3/22
Source: Dr. Andre Uddin  (11/22/22)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report. More >

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock
Source: Dr. Yale Jen  (11/22/22)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report. More >

Global Drug Co. Offers US$1.35B To Boost Hematology Assets
Source: Streetwise Reports  (11/22/22)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share. More >

FDA Awards Breakthrough Therapy Status for AMD Drug
Source: Streetwise Reports  (11/21/22)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration. More >

Pharma Co. Won't See Bump in Sales From New COVID Drug
Source: Dr. Andre Uddin  (11/18/22)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report. More >

Biopharma Co. Hopes To Turn US$30M Into US$2B
Source: Streetwise Reports  (11/17/22)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types. More >

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data
Source: Streetwise Reports  (11/16/22)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration. More >

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment
Source: Streetwise Reports  (11/14/22)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon. More >

UK Co. Buys NARCAN® Nasal Spray Maker
Source: Streetwise Reports  (11/14/22)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met. More >

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says
Source: Streetwise Reports  (11/11/22)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts. More >

Biologics Co. Doubles Revenue in Q3/22
Source: Streetwise Reports  (11/11/22)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million. More >

Pharma Co. Trades 200% Higher
Source: Streetwise Reports  (11/10/22)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma. More >

Nine Stocks Expert Says Should Pique Your Interest
Source: Clive Maund  (11/9/22)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on. More >

Clean Nuclear Med Tech With Quantum Blue Sky
Source: Penny Queen  (11/9/22)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention. More >

Healthcare Firm Offers US$295M for Ophthalmology Co.
Source: Streetwise Reports  (11/8/22)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share. More >

Pharma Co. Signs Global License Deal for Eye Drops
Source: Streetwise Reports  (11/8/22)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances. More >

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines
Source: Streetwise Reports  (11/3/22)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide. More >

Pharma Co. Earns Big Rewards from Global License Deal
Source: Streetwise Reports  (11/2/22)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue. More >

Biopharma Co. Trades 39% Higher
Source: Streetwise Reports  (11/1/22)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant. More >

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current
  (10/31/22)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report. More >

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial
Source: Streetwise Reports  (10/28/22)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer. More >